Discounted Cash Flow Rating

Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Strong Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Buy

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Alpine Immune Sciences, Inc. Common Stock (ALPN)

Pharmaceutical Preparations

https://www.alpineimmunesciences.com

Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

188 EAST BLAINE ST., SUITE 200
SEATTLE, WA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/17/2015

Market Cap

4,456,779,835

Shares Outstanding

58,000,000

Weighted SO

58,097,961

Total Employees

N/A

Upcoming Earnings

08/12/2024

Similar Tickers

TERN --.--%

DAWN --.--%

ABOS --.--%

AMLX --.--%

MLTX --.--%

ANEB --.--%

ADAG --.--%

ACRV --.--%

Beta

0.9690

Last Div

0.0000

Range

8.33-65.0

Chg

0.0100

Avg Vol

2371991

Mkt Cap

4456779835

Exch

NASDAQ

Country

US

Phone

206 788 4545

DCF Diff

40.3771

DCF

-0.1471

Div Yield

0.0000

P/S

78.8518

EV Multiple

-97.6180

P/FV

12.5043

Div Yield %

0.0000

P/E

-112.9391

PEG

-1.7925

Payout

0.0000

Current Ratio

9.5617

Quick Ratio

9.4982

Cash Ratio

1.0241

DSO

3.5066

DIO

0.0006

Op Cycle

3.5072

DPO

2610.7204

CCC

-2607.2132

Gross Margin

0.9897

Op Margin

-0.9086

Pretax Margin

-0.6499

Net Margin

-0.6517

Eff Tax Rate

-0.0018

ROA

-0.0986

ROE

-0.1486

ROCE

-0.1504

NI/EBT

1.0028

EBT/EBIT

0.7153

EBIT/Rev

-0.9086

Debt Ratio

0.0258

D/E

0.0290

LT Debt/Cap

0.0255

Total Debt/Cap

0.0282

Int Coverage

305.6786

CF/Debt

-8.3428

Equity Multi

1.1231

Rec Turnover

104.0902

Pay Turnover

0.1398

Inv Turnover

583000.0000

FA Turnover

6.5169

Asset Turnover

0.1513

OCF/Share

-1.2579

FCF/Share

-1.2644

Cash/Share

4.7735

OCF/Sales

-1.4251

FCF/OCF

1.0051

CF Coverage

-8.3428

ST Coverage

-84.7895

CapEx Coverage

-195.0363

Div&CapEx Cov

-195.0363

P/BV

12.5043

P/B

12.5043

P/S

78.8518

P/E

-112.9391

P/FCF

-55.0471

P/OCF

-51.6477

P/CF

-51.6477

PEG

-1.7925

P/S

78.8518

EV Multiple

-97.6180

P/FV

12.5043

DPS

0.0000

Latest Headlines (EST)

Benzinga Dec 22, 07:33 Tesla To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday Benzinga Nov 15, 12:00 The Latest Analyst Ratings for Alpine Immune Sciences

Revenue Product Segmentation